{"id":7225,"date":"2012-04-22T15:09:44","date_gmt":"2012-04-22T15:09:44","guid":{"rendered":"http:\/\/cardiophile.org\/?p=7225"},"modified":"2012-04-22T15:09:44","modified_gmt":"2012-04-22T15:09:44","slug":"dabigatran-etexilate-a-newer-anticoagulant","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/","title":{"rendered":"Dabigatran etexilate"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Dabigatran etexilate<\/span><\/h2>\n<p>Dabigatran etexilate is a <em><strong>prodrug<\/strong><\/em> without any anticoagulant activity. It gets converted in vivo to the active form dabigatran, which is a specific, reversible, direct thrombin inhibitor that inhibits both fibrin-bound as well as free thrombin. The drug\u00a0inhibits coagulation of blood by preventing thrombin-mediated effects like thrombin-induced platelet aggregation, breakdown of fibrinogen to fibrin monomers and the activation of clotting factors V, VIII, XI and XIII.<\/p>\n<p><strong><span style=\"color: #0000ff;\">Indications<\/span><\/strong><\/p>\n<p>It is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for postoperative thromboprophylaxis in patients who have undergone total hip or knee replacement procedures.<\/p>\n<p><strong><span style=\"color: #0000ff;\">Contraindications<\/span><\/strong><\/p>\n<p>Contraindications to the drug\u00a0would include serious hypersensitivity (anaphylaxis) to dabigatran and active pathological bleeding.<\/p>\n<p><strong><span style=\"color: #0000ff;\">Precautions<\/span><\/strong><\/p>\n<p>Dabigatran should be used with <em>caution in patients with severe renal impairment<\/em> having Cl<sub>cr<\/sub>\u00a0in the range of 15-30ml\/min. Use of dabigatran etexilate in patients with Cl<sub>cr<\/sub>\u00a0&lt; 15 ml\/min is not recommended due to insufficient evidence to support use in this group.<\/p>\n<p><span style=\"color: #0000ff;\"><strong>Drug interactions<\/strong><\/span><\/p>\n<p>Drug interactions are in general rare with dabigatran etexilate unlike warfarin as cytochrome P-450 is not involved in the metabolism. But P-glycoprotein inducers like rifampicin should be avoided in combination with dabigatran. Food has no effect on the bioavailability of dabigatran but delays the time to peak concentrations by 2 hours.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. <\/p>\n","protected":false},"author":1,"featured_media":39401,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-7225","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dabigatran etexilate \u2013 an anticoagulant for stroke prevention<\/title>\n<meta name=\"description\" content=\"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dabigatran etexilate \u2013 an anticoagulant for stroke prevention\" \/>\n<meta property=\"og:description\" content=\"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T15:09:44+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Dabigatran etexilate\",\"datePublished\":\"2012-04-22T15:09:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/\"},\"wordCount\":221,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/\",\"name\":\"Dabigatran etexilate \u2013 an anticoagulant for stroke prevention\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T15:09:44+00:00\",\"description\":\"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/dabigatran-etexilate-a-newer-anticoagulant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dabigatran etexilate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dabigatran etexilate \u2013 an anticoagulant for stroke prevention","description":"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/","og_locale":"en_US","og_type":"article","og_title":"Dabigatran etexilate \u2013 an anticoagulant for stroke prevention","og_description":"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.","og_url":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T15:09:44+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Dabigatran etexilate","datePublished":"2012-04-22T15:09:44+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/"},"wordCount":221,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/","url":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/","name":"Dabigatran etexilate \u2013 an anticoagulant for stroke prevention","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T15:09:44+00:00","description":"Dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/dabigatran-etexilate-a-newer-anticoagulant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Dabigatran etexilate"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=7225"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7225\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=7225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=7225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=7225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}